Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation.
about
Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1Epidemiology and genetics of ventricular fibrillation during acute myocardial infarctionThe persistent sodium current blocker riluzole is antiarrhythmic and anti-ischaemic in a pig model of acute myocardial infarction[Diagnosis of ischemia and revascularization in patients with ventricular tachyarrhythmia].The clinical challenge of preventing sudden cardiac death immediately after acute ST-elevation myocardial infarction.Overexpression of M₃ muscarinic receptor is a novel strategy for preventing sudden cardiac death in transgenic mice.Optogenetic determination of the myocardial requirements for extrasystoles by cell type-specific targeting of ChannelRhodopsin-2.KATP Channels in the Cardiovascular System.miRNAs at the heart of the matter.Control of cardiac excitability by microRNAs.Ischemic ventricular arrhythmias: experimental models and their clinical relevanceActions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts.Rat Models of Ventricular Fibrillation Following Acute Myocardial Infarction.Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats.Nitric oxide fails to confer endogenous antiarrhythmic cardioprotection in the primate heart in vitro.Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?Mitochondria, the calcium uniporter, and reperfusion-induced ventricular fibrillation.Central Sympathetic Activation and Arrhythmogenesis during Acute Myocardial Infarction: Modulating Effects of Endothelin-B Receptors.Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids.Riluzole reduces arrhythmias and myocardial damage induced by coronary occlusion in anaesthetized pigs.Effects of pre- and postconditioning on arrhythmogenesis in the in vivo rat model.Blunted proarrhythmic effect of nicorandil in a Langendorff-perfused phase-2 myocardial infarction rabbit model.Neutrophil ablation with anti-serum does not protect against phase 2 ventricular arrhythmias in anaesthetised rats with myocardial infarction.
P2860
Q24651215-0F074BA8-5B1A-4BF3-B31F-26FABBBF6082Q28072276-AE4791F7-E6A8-47DF-B0B3-DD1CCDE97842Q28748172-4883F4D3-F1DC-4590-90DD-F16CD7ECB075Q30313114-C8523A17-A178-4D54-9937-7CAB35D87A67Q33164931-752816A5-5E83-4B20-8303-AABFFAEA94F9Q35876776-B55C5222-571B-4A96-8489-6E2F0C5DC9D1Q35961333-2431E7EF-6C43-4C22-8F15-2A70DB50E68EQ36422478-75BBD9B8-939F-4712-8A6A-00FCC6B83263Q36785011-D0E864DB-93CA-4753-A501-F542B0404DEFQ37211498-D4B83219-42C8-4639-8CF5-2604C32D7D70Q37899322-8A1E21A3-0160-42BF-8BE4-1ED43E471931Q38756794-C44D58ED-57C2-43EF-AF1D-4231B01438C9Q39222500-C4B1A3F2-0102-43EA-959F-B7F06B2E762CQ41429462-CFABA625-25E6-4EB6-918A-16F538534B6CQ41584845-97431DDC-3FA3-4571-8A9E-F72D70B39A3EQ41594309-F5B503F9-FC2A-412B-AADE-63CEF1DA7009Q41604495-0BC0BE02-F3BC-4D01-A3C0-6ACBB0119D83Q42108029-CBE7802A-8EE4-4E1E-985E-EB27CCC270C8Q42572010-16C0249B-BEB1-44E2-BB53-181BF3E905C1Q44620461-5FC1B30F-4869-4244-96B4-B5482D7A6379Q45205640-887CD163-8812-4610-B95C-2AFEF0452EAAQ45736067-1BA195E4-8F0F-4C32-BB3A-58E77372A400Q48625905-A58D80A7-7E63-4A58-A2F2-4D70BD33593B
P2860
Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@ast
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@en
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@nl
type
label
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@ast
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@en
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@nl
prefLabel
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@ast
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@en
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@nl
P2093
P2860
P356
P1476
Phase 2 ventricular arrhythmia ...... afety pharmacology evaluation.
@en
P2093
David J Hearse
Hugh Clements-Jewery
Michael J Curtis
P2860
P304
P356
10.1038/SJ.BJP.0706231
P407
P577
2005-07-01T00:00:00Z